Quality of life is the fundamental criterion of the efficacy of targeted therapy in patients with metastatic Her2-positive breast cancer


Cite item

Full Text

Abstract

Since the 1990s, the unique data of clinical trials has been analyzed regarding the Quality of Life (QoL) Index as a one of fundamental criteria of treatment efficacy for malignant tumors and breast cancer in particular. Last decades the highest progress was shown in the treatment of HER2-positive subtype of BC. New biological therapy with anti-HER2 targeted agents (pertuzumab and T-DM1) significantly improve overall survival in HER2-positive BC, increase disease-control rate and associated with good quality of life. QoL measurement by special Questionnaires is a simple and accurate option to evaluate the patient's reaction to disease and its treatment in detail.

About the authors

T Yu Semiglazova

N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation; I.I.Mechnikov State Northwestern Medical University of the Ministry of Health of the Russian Federation

Email: tsemiglazova@mail.ru
д-р мед. наук, рук. отд. инновационных методов терапевтической онкологии и реабилитации ФГБУ НИИ онкологии им. Н.Н.Петрова, доц. каф. онкологии ГБОУ ВПО СЗГМУ им. И.И.Мечникова 197758, Russian Federa- tion, Saint Petersburg, pos. Pesochnyi, ul. Leningradskaia, d. 68

G A Dashyan

N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation

д-р мед. наук, вед. науч. сотр. отд-ния опухолей молочной железы ФГБУ НИИ онкологии им. Н.Н.Петрова 197758, Russian Federa- tion, Saint Petersburg, pos. Pesochnyi, ul. Leningradskaia, d. 68

V V Semiglazov

I.M.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation

д-р мед. наук, зав. каф. онкологии СПбГМУ им. акад. И.П.Павлова 197022, Russian Federation, Saint Petersburg, ul. L'va Tolstogo, d. 6/8

A S Zhabina

N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation

канд. мед. наук, науч. сотр. отд. инновационных методов терапевтической онкологии и реабилитации ФГБУ НИИ онкологии им. Н.Н.Петрова 197758, Russian Federa- tion, Saint Petersburg, pos. Pesochnyi, ul. Leningradskaia, d. 68

M A Osipov

N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation

врач-онколог амбулаторно-консультативного отд-ния ФГБУ НИИ онкологии им. Н.Н.Петрова 197758, Russian Federa- tion, Saint Petersburg, pos. Pesochnyi, ul. Leningradskaia, d. 68

Z S Kotova

N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation

197758, Russian Federa- tion, Saint Petersburg, pos. Pesochnyi, ul. Leningradskaia, d. 68

V V Klimenko

N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation; I.I.Mechnikov State Northwestern Medical University of the Ministry of Health of the Russian Federation

аспир. отд. инновационных методов терапевтической онкологии и реабилитации ФГБУ НИИ онкологии им. Н.Н.Петрова, доц. каф. онкологии ГБОУ ВПО СЗГМУ им. И.И.Мечникова 197758, Russian Federa- tion, Saint Petersburg, pos. Pesochnyi, ul. Leningradskaia, d. 68

P V Krivorotko

N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation; I.I.Mechnikov State Northwestern Medical University of the Ministry of Health of the Russian Federation

д-р мед. наук, зам. глав. врача по лечебной работе ФГБУ НИИ онкологии им. Н.Н.Петрова, доц. каф. онкологии ГБОУ ВПО СЗГМУ им. И.И.Мечникова 197758, Russian Federa- tion, Saint Petersburg, pos. Pesochnyi, ul. Leningradskaia, d. 68

V F Semiglazov

N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation; I.I.Mechnikov State Northwestern Medical University of the Ministry of Health of the Russian Federation

чл.-кор. РАН, д-р мед. наук, проф., рук. отд. репродуктивной онкологии ФГБУ НИИ онкологии им. Н.Н.Петрова, проф. каф. онкологии ГБОУ ВПО СЗГМУ им. И.И.Мечникова 197758, Russian Federa- tion, Saint Petersburg, pos. Pesochnyi, ul. Leningradskaia, d. 68

References

  1. Ионова Т.И., Новик А.А., Сухонос Ю.А. Понятие качества жизни больных онкологического профиля. Онкология. 2000; 2 (1-2): 25-8.
  2. Aaronson N, Cull A, Kaasa S, Sprangers M. The European Organization for Research and Treatment of Cancer (EORTC) modular approach to quality of life assessment in oncology. Int О Ment Health 1994; 23: 75-96.
  3. Lemieux J, Goodwin P, Bordeleau L et al. Quality - of - life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009). J Natl Cancer Inst 2011; 103: 178-231.
  4. Семиглазова Т.Ю., Семиглазов В.В., Филатова Л.В. и др. Качество жизни - важный критерий эффективности таргетной терапии метастатического поражения скелета при раке молочной железы. Опухоли женской репродуктивной системы. 2013; 1-2: 17-22.
  5. Paraskevi T. Quality of life outcomes in patients with breast cancer. Licensee PAGEPress. Italy Oncol Rev 2012; 6: e2: 7-10.
  6. Osoba D, Hsu M, Copley-Merriman C et al. Stated preferences of patients with cancer for health - related quality - of - life (HRQOL) domains during treatment. Qual Life Res 2006; 15: 273-83.
  7. Montazeri А. Health - related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007. J Exper & Clin Cancer Research 2008; 27: 32.
  8. Eton D, Cella D, Yost K et al. A combination of distribution and anchor - based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epid 2004; 57: 898-910.
  9. Fisher B, Osborn K, Margolese R et al. Neoplasms of the breast. Cancer med 1993; 3: 1706-74.
  10. Brady M, Cella D, Mo F et al. Reliability and validity of the functional assessment of cancer therapy - breast quality - of - life instrument. J Clin Oncol 1997; 15: 974-86.
  11. Lemieux J, Goodwin P, Bordeleau L et al. Quality - of - life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009). J Nat Cancer Inst 2011; 103: 178-231.
  12. Perry S, Kowalski T, Chang C. Quality of life assessment in women with breast cancer: benefits, acceptability and utilization. Health Qual Life Outcomes 2007; 5: 24-38.
  13. Cella D, Wang M, Wagner L, Miller K. Survival - adjusted health related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab vs. paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100). Breast Cancer Res Treat 2011; 130: 855-61.
  14. Walker M, Hasan M, Yim Y et al. Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients. Health Qual Life Outcomes 2011; 9: 46.
  15. Corey-Lisle P, Peck R, Mukhopadhyay P et al. Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer. Cancer 2012; 118: 461-8.
  16. Sherrill B, Di Leo A, Amonkar M et al. Quality - of - life and quality - adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first - line treatment for metastatic breast cancer. Curr Med Res Opin 2010; 26: 767-75.
  17. Zhou X, Cella D, Cameron D et al. Lapatinib plus capecitabine vs. capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality - of - life assessment. Breast Cancer Res Treat 2009; 117: 577-89.
  18. Rugo H, Brammer M, Zhang F et al. Effect of trastuzumab on health - related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials. Clin Breast Cancer 2010; 10: 288-93.
  19. Мерабишвили В.М. Эпидемиология и выживаемость больных раком молочной железы. Вопр. онкологии. 2013; 59 (3): 314-9.
  20. Семиглазов В.Ф., Палтуев Р.М., Семиглазова Т.Ю. и др. Опухоли репродуктивной системы. М.: Рекламно - издательская группа МегаПро, 2013.
  21. Baselga J, Cortes J, Kim S et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-19.
  22. Swain S, Cortes J, Semiglazov V et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEO- PATRA study): overall survival results from a randomized, double - blind, placebo - controlled, phase 3 study. Lancet Oncol 2013; 14: 461-71.
  23. Cortés J, Baselga J, Im Y.-H. Health - related quality - of - life assessment
  24. in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol 2013; 24 (10): 2630-5.
  25. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-91. Erratum in N Engl J Med 2013; 368: 2442.
  26. Welslau М, Dieras V, Sohn J-H. Patient-Reported Outcomes From EMILIA, a Randomized Phase 3 Study of Trastuzumab Emtansine (T-DM1) Versus Capecitabine and Lapatinib in Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Breast Cancer. Cancer 2014; p. 642-51.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies